July 15, 2025

Data from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer

View Full Paper

Ask AI

Bookmark

PF-06873600 was shown to have a recommended dose of 25 mg twice daily based on safety assessments in 78 patients.
Common adverse events included nausea (62.9%), anemia (44.4%), and fatigue (43.7%), demonstrating safety concerns.
The study recorded reductions in Ki67-positive cells and ctDNA, indicating effective pharmacodynamics during treatment.
Preliminary clinical activity included three partial responses with an objective response rate of 22.7% among specific breast cancer patients.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Phase I/IIa trial shows safety and preliminary efficacy of PF-06873600 in patients with breast cancer, highlighting its promise in hormone receptor+ types.

Cite This Study

Yap et al. (2025) studied this question.

synapsesocial.com/papers/689a02bce6551bb0af8cc6c6 https://doi.org/10.1158/1078-0432.c.7928417

View Full Paper

Ask AI

Bookmark

Implication

Phase I/IIa trial shows safety and preliminary efficacy of PF-06873600 in patients with breast cancer, highlighting its promise in hormone receptor+ types.

Data from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer

Key Points

Discussion

Implication

Cite This Study

Data from First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider